An outcomes analysis of anterior epistaxis management in the emergency department

E. Newton1, A. Lasso3, W. Petrich3 and S. J. Kilty2,3*

Abstract
Background: Many treatment options exist for the management of anterior epistaxis. However, little is known about treatment outcomes. The objective was to identify the currently utilised methods of management and outcomes for patients with anterior epistaxis presenting to the emergency department (ED) at a Canadian tertiary care center.

Methods: A retrospective review of ED visits from January 2012-May 2014 for adult patients with a diagnosis of anterior epistaxis was performed. Patient demographic data, comorbidities, and treatment methods were documented. The effectiveness of different treatment modalities was determined.

Results: Three hundred fifty-three primary anterior epistaxis cases were included. Mean patient age was 70 years and 49 % of patients were female. Comorbidities included hypertension (56 %), diabetes (19 %), CAD (28 %), and atrial fibrillation (27 %). A large proportion of the cohort (61 %) was on at least one anticoagulant or antiplatelet therapy. The most common utilised treatment modalities were silver nitrate cauterization, Merocel®, petroleum gauze packing, nasal clip and 15 % were simply observed. Initial treatment success was achieved in 74 % of cases. Of patients receiving specific treatment modalities, silver nitrate cauterization had the highest success rate at 80 %. 26 % of patients returned to the ED for recurrence of epistaxis with highest rates occurring in the nasal clip (59 %), Merocel® (26 %), and petroleum gauze packing (42 %) groups.

Conclusions: The differences in recurrence rate among the different treatment modalities observed may be due to true differences in effectiveness or differences in treatment selection by the ED physicians based on severity of epistaxis. Cauterization with silver nitrate, however, offers the added benefit of no need for follow up. Further study is needed to elucidate the most efficacious treatment modality based on epistaxis severity.

Keywords: Epistaxis, Treatment, Anterior epistaxis, Tertiary care, Emergency department
literature evaluating these modalities and their effectiveness when utilised in the ED. Further, at this time there are no widely accepted treatment guidelines and treatment selection is a matter of individual ED physician preference.

**Importance**
Considering that anterior epistaxis is a very common and treatable condition it is important to optimize efficiency and effectiveness when treating this disorder. Although, there is evidence for each individual treatment modality, the literature is deficient as to current ED physician practices and the outcomes for use of the many modalities.

**Goals of this investigation**
The purpose of this study was twofold, first to assess the current practices utilised in a Canadian Tertiary Care center for anterior epistaxis management and second, to evaluate the outcomes of these treatments.

**Methods**

**Study design and setting**
With the approval of the Research Ethics Board at the Ottawa Hospital Research Institute a retrospective review of all patient visits to the ED at The Ottawa Hospital (TOH), a Canadian tertiary care center, with a primary diagnosis of anterior epistaxis during the period of January 2012 to May 2014 was performed.

**Selection of participants**
Adult patients with a primary diagnosis of epistaxis in the emergency department were included in this study. Records were identified by the health records department using the ICD-10 code for epistaxis (R04.0). The epistaxis codes do not differentiate between anterior and posterior epistaxis; thus all records were hand searched and patients with a diagnosis of posterior epistaxis or concurrent anterior and posterior epistaxis were excluded. Patients that presented with epistaxis due to a complication of pre-existing conditions such as end stage cancer were excluded. Patients who died during the ED visit for reasons other than epistaxis were also excluded. Patients with an initial visit to the ED for packing removal that had been placed at a different institution and patients who were treated as posterior epistaxis despite having an anterior epistaxis diagnosis were also excluded. Patients who received treatment with a modality that was used in five or fewer cases were also excluded from analysis. See Fig. 1 for study flow chart.

**Methods and measurements**
From the identified charts data was abstracted including patient demographics, comorbidities, the treatment modalities used, course in the emergency department, admission, concurrent medical disorders, medications and finally recurrence or ED follow-up information. Treatment modalities identified for data abstraction included conservative (no treatment), nasal clip, petroleum gauze

---

**Fig. 1 Study flowchart**

419 initial visits to ED with an ICD-10 R04.0 diagnosis

Data Collection from medical charts

Excluded patients (n=66)
- Posterior epistaxis (n=44)
- Died due to reasons other than epistaxis during the ED visit (n=5)
- Initial visit to ED was for packing removal that had been done at a different institution (n=4)
- Discharge treatments was posterior pack despite having an anterior epistaxis diagnosis (n=3)
- Treatment with 5 or fewer observations (n=10)

Data analysis (n=353)
packing, Merocel® packing, Floseal®, Surgicel®, Epistat®, silver nitrate cautery, electrocautery, endoscopic surgery, arterial embolization and other treatments not otherwise specified (NOS). The “other packing” group in this study received anterior petroleum gauze packing or equivalent.

Outcomes
For each treatment modality, success was defined as patients who were diagnosed with anterior epistaxis, who received treatment and did not present with a recurrence within 14 days of their original date of presentation [11]. Conversely, failure was defined as the patients who had an ipsilateral recurrence of epistaxis within 14 days of initial treatment. The treatment type was recorded based on the treatment modality used to arrest the bleeding that led to the patient’s discharge from the ED. Follow-up was defined as patients who were administered a specific treatment and who were subsequently booked and received follow-up care in the ED for either packing removal or to check the site of epistaxis or for any other reason. For patients requiring an inpatient admission, the length and reason for admission were recorded.

Analysis
All statistical calculations were done using SAS (version 9.3). Categorical variables were summarized using frequency counts and percentages, while continuous variables were summarized using the mean (SD) or median (IQR), as appropriate. Where necessary, initial testing for associations between categorical variables was done using either chi-square or Fisher’s Exact tests. Modeling of categorical outcomes was done using logistic regression.

Results
Characteristics of study subjects
A total of 419 visits to the ED with a primary diagnosis of epistaxis occurred from January 2012 to May 2014. Sixty-six visits were excluded from this analysis, reasons for exclusion are shown in Fig. 1. Overall, 353 anterior epistaxis cases were included in this study; the demographics and comorbidities are summarized in Table 1. The individuals included in this study had a mean age of 70 and 49% were women. A large proportion (61%) of the patients were on some type of anticoagulant or antiplatelet medication. Of the comorbidities recorded, hypertension, diabetes, coronary artery disease, atrial fibrillation, did not have a statistically significant impact on treatment failure ($p > 0.05$).

Main results
The outcome of each treatment is summarized in Table 2. In all, the overall primary treatment failure rate was 26% (91 patients) and in total 26.6% (94 patients) returned to the ED for a scheduled follow-up after discharge from the ED. Of the individuals requiring follow-up, 89 (95%) returned for packing removal (53 patients had Merocel® packing), in 3 (3.1%) patients packing was left in situ at the follow up visit and 2 (2.1%) patients attended the follow up visit even though their packing had fallen out on its own before their appointment. Of the 94 patients requiring follow up, 22 (23%) required further intervention (10 patients with Merocel® packing) for epistaxis at the time packing removal. There was no difference in bleeding rates post pack removal between the different types of packing.

When silver nitrate was compared to petroleum gauze packing, those in silver nitrate group were less likely to fail (OR 0.335, 95% CI 0.160–0.703, $p = 0.0038$). When silver nitrate was compared to Merocel® packing, the odds of recurrence were lower with silver nitrate than with Merocel® (OR 0.694, 95% CI 0.364–1.322, $p = 0.27$), however this was not statistically significant.

When evaluating potential risk factors for the development of epistaxis, anticoagulation was identified as a risk factor for treatment failure (OR 2.53, 95% CI 1.20–5.35, $p = 0.014$). When silver nitrate was compared to Merocel® packing, the odds of recurrence were lower with silver nitrate than with Merocel® (OR 0.694, 95% CI 0.364–1.322, $p = 0.27$), however this was not statistically significant.

When evaluating potential risk factors for the development of epistaxis, anticoagulation was identified as a risk factor for treatment failure (OR 2.53, 95% CI 1.20–5.35, $p = 0.014$). When silver nitrate was compared to Merocel® packing, the odds of recurrence were lower with silver nitrate than with Merocel® (OR 0.694, 95% CI 0.364–1.322, $p = 0.27$), however this was not statistically significant.

When evaluating potential risk factors for the development of epistaxis, anticoagulation was identified as a risk factor for treatment failure (OR 2.53, 95% CI 1.20–5.35, $p = 0.014$). When silver nitrate was compared to Merocel® packing, the odds of recurrence were lower with silver nitrate than with Merocel® (OR 0.694, 95% CI 0.364–1.322, $p = 0.27$), however this was not statistically significant.

**Table 1** Patient demographics

| Characteristic          | Value     |
|-------------------------|-----------|
| Age mean y (range),     | 70 (14–97) |
| Sex no. (%)             |           |
| Male                    | 180 (51)  |
| Female                  | 173 (49)  |
| Comorbidities N (%)     |           |
| Hypertension            | 198 (56)  |
| Diabetes                | 67 (19)   |
| CAD                     | 97 (28)   |
| Afib                    | 94 (27)   |
| HHT                     | 3 (1)     |
| Other blood disorders   | 12 (3)    |
| AC/AP medication use    | 217 (62)  |

*a Coronary artery disease  
*b Atrial fibrillation  
*c Hereditary hemorrhagic telangiectasia  
*d Anticoagulation or antiplatelet

**Table 2** Treatment outcomes for management of anterior epistaxis

| Treatment         | N (%) | Failure N (%) |
|-------------------|-------|---------------|
| Silver nitrate    | 122 (35) | 24 (20)       |
| Merocel           | 92 (26)  | 24 (26)       |
| No treatment      | 54 (15)  | 11 (20)       |
| Other packing$a$  | 45 (13)  | 19 (42)       |
| Other$b$          | 23 (6)   | 3 (13)        |
| Nasal clip        | 17 (5)   | 10 (59)       |

$a$ Other packing included non-dissolvable anterior packs the majority being Vaseline gauze packing  
$b$ Other included surgicel, decongestant with topical anesthetic alone
from the patient characteristics, through logistical regression. The type of anticoagulant or antiplatelet medication individuals in the study were receiving is summarized in Table 3. Given the large variety of anticoagulation and antiplatelet medications, they were grouped into 3 categories for analysis as seen in Table 4. Overall, 61% of the individuals were on at least one antiplatelet or anticoagulant medication. Of those not on any anticoagulant or antiplatelet agent, the failure rate for anterior epistaxis treatment was 18%. In contrast, for individuals on any anticoagulant/antiplatelet agent the failure rate was 30%. There was a statistically significant association between the use of anticoagulant/antiplatelet medication and the recurrence of epistaxis ($p = 0.0119$). 73% of all patients who failed treatment were on at least one antiplatelet or anticoagulant medication.

**Discussion**

Overall there were 353 cases of anterior epistaxis analyzed in this study for outcomes of treatment received in the ED. Silver nitrate cautery was the most popular modality used accounting for 35% of initial treatment. However, the treatment of anterior epistaxis proved to be quite variable with Merocel®, petroleum gauze packing/other packing or a nasal clip commonly being used.

The group of patients who received no treatment at the ED was not used as a control to compare other treatment modalities given those patients not requiring treatment had stopped bleeding when seen by the ED physician or they did not have a bleeding episode of such a severity that it required any treatment. It would be an unfair comparison due to the inherent clinical difference in epistaxis severity. When the silver nitrate group was compared to the petroleum gauze packing, those in silver nitrate group were less likely to fail ($p = 0.0038$).

| Medication               | N (%)  |
|-------------------------|--------|
| Any AC/AP               | 217 (62) |
| ASA                     | 122 (34) |
| Coumadin                | 78 (23) |
| Rivaroxaban             | 14 (4) |
| Dabigatran              | 4 (1) |
| Apixaban                | 4 (1) |
| Clopidogrel             | 33 (9) |
| Ticagrelor              | 2 (1) |
| Other anticoagulant     | 7 (2) |

| Anticoagulant/Antiplatelet | N   | Failure N (%) |
|---------------------------|-----|---------------|
| None                      | 136 | 25 (18)       |
| Any anticoagulant/antiplatelet | 217 | 66 (30)   |
| ASA only                  | 85  | 28 (33)       |
| Other regimen             | 132 | 38 (29)       |

In this cohort, silver nitrate treatment had the lowest rate of treatment failure (20%) of the most utilised treatment modalities and it also had the added benefit of not requiring an additional routine ED visit, as non-dissolvable packing did. Selection bias may have affected this observation as silver nitrate may have been used by ED physicians only in less severe cases. Other literature has described good success rates for anterior dissolvable packing [3, 4, 11, 12] and surgical techniques [3], however the number of individuals receiving these treatments in our cohort were too small for analysis.

Epistaxis management, as with any medical condition, should be tailored to the patient and the clinical situation [8]. In this study most patients with anterior epistaxis received successful management with silver nitrate cautery or Merocel® packing being the most commonly used modalities. Silver nitrate was particularly advantageous as it showed promising results insofar as treatment success without a need for follow-up. However, in these cases the site of bleeding was identifiable on anterior rhinoscopy examination and amenable to cautery with silver nitrate. This is in keeping with other studies which have shown that when the source of bleeding in epistaxis is identifiable chemical cautery has excellent success in the treatment of anterior epistaxis [2, 8–10].

Exploring the reasons for treatment failure, the use of blood thinners is largely believed to have an effect. In our study it was found that being on any anticoagulant or antiplatelet agent, including ASA, significantly increased the odds of recurrence after discharge from the ED ($p = 0.0106$). The rate of treatment failure in patients on any anticoagulant/antiplatelet agent was 30%, in ASA alone was 33% and in another regimen was 29%, these were significantly greater than the failure rate of 18% seen in the individuals not on any such therapy ($p < 0.0119$).

As with any study, this study has some limitations. The population size studied was not large enough to accurately comment on less commonly used forms of management for anterior epistaxis. Similarly, there was no data or rating on the severity of epistaxis on arrival to the ED that, in the end, may have affected physician treatment selection and also affected recurrence. This
may confound the relationship between the treatment modality used and outcomes. At the institution of this study, patients presenting acutely with anterior epistaxis are seen first by an emergency physician, who may or may not utilise nasal endoscopy if the bleeding site is not readily identifiable on anterior rhinoscopy. Similarly, a standardized approach to patient evaluation prior to treatment selection was not utilised for the patients in this series. A standard approach to patient evaluation for anterior epistaxis such as the application of a topical decongestant/vasoconstrictor and analgesia prior to assessment for a bleeding site is needed. Given that the decision to use cautery requires visualization of the bleeding site the choice between packing and cautery for an ED physician may then have been affected. Further, there may also have been patients who were lost to follow up due to ED visits at other locations in the case of re-bleeding. Despite the limitations in this study, the large patient population allowed for informative evaluation of the treatment data.

Conclusions

In summary, the current practices for the treatment of anterior epistaxis in the ED are quite variable. There are many modalities currently in use and there is not yet an accepted evidence-based recommendation to help guide treatment decisions. Looking at the four most common modalities used to treat anterior epistaxis in the ED from this study, the use of silver nitrate appears to be an effective management option taking into account the time and resources used for any other modality necessitating a patient to return to the ED. This suggests that if the anterior site of bleeding is identifiable, it is likely amenable to chemical cautery, silver nitrate be the first line treatment. However, due to limitations of the study, and that there was no grading system to identify epistaxis severity, a recommendation of silver nitrate cautery for all occurrences of anterior epistaxis cannot be given at this time. Further study is needed to determine the most efficacious treatment modality based on epistaxis severity.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SK conceived the study, and obtained ethics approval. SK supervised the conduct of the trial and data collection. EN and AL undertook collecting patient data, and management of the. EN, AL and WP provided statistical advice on study design and helped analyze the data. EN drafted the manuscript, and all authors contributed substantially to its revision. SK takes responsibility for the paper as a whole. All authors read and approved the final manuscript.

Author details

1University of Ottawa, Ottawa, ON, Canada. 2Department of Otolaryngology - Head and Neck Surgery, University of Ottawa, Ontario, Canada. 3Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada.

Received: 18 December 2015 Accepted: 4 April 2016

Published online: 11 April 2016

References

1. Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo Jr CA. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005;46:77–81.
2. Vliehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg. 2006;64:511–8.
3. Abdelkader M, Leong SC, White PS. Endoscopic control of the sphenopalatine artery for epistaxis: long-term results. J Laryngol Otol. 2007;121:759–62.
4. Bachelet JT, Bourlet J, Glezal A. Hemostatic absorbable gel matrix for severe post-traumatic epistaxis. Rev stomatol Chir Maxillofac Chir Orale. 2013;114:310–4.
5. Badran K, Malik TH, Bellosa A, Timms MS. Randomized controlled trial comparing Merocel and RapidRhino packing in the management of anterior epistaxis. Clin Otolaryngol. 2005;30:333–7.
6. Biggs TC, Baruah P, Mainwaring J, Harries PG, Salib RJ. Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients. J Laryngol Otol. 2013;127:483–8.
7. Killick N, Malik V, Nirmal Kumar B. Nasal packing for epistaxis: an evidence-based review. Br J Hosp Med (London, England: 2005). 2014;75:143–4.
8. Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician. 2005;71:305–11.
9. Morgan DJ, Kellerman R. Epistaxis: evaluation and treatment. Prim Care. 2014;41:63–73.
10. Toner JG, Walby AP. Comparison of electro and chemical cautery in the treatment of anterior epistaxis. J Laryngol Otol. 1990;104:461–7.
11. Kilty SJ, Al-Hajry M, Al-Mutairi D, et al. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis. Laryngoscope. 2014;124:38–42.
12. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope. 2005;115:899–902.